Detalhe da pesquisa
1.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
N Engl J Med
; 385(27): 2531-2543, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965338
2.
First effects of rising amyloid-ß in transgenic mouse brain: synaptic transmission and gene expression.
Brain
; 138(Pt 7): 1992-2004, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25981962
3.
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Lancet HIV
; 9(9): e627-e637, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35868341
4.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Lancet HIV
; 9(9): e638-e648, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055295
5.
A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.
Cell Rep
; 10(4): 633-44, 2015 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25620700